This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make Billions

By Alex Knapp, Forbes Staff in alexknappblog, Daily Cover, Editors' Pick, Forbes, healthcare, technology
July 25, 2023

Benjamin Oakes’ Scribe Therapeutics is developing specialized Crispr proteins for multiple diseases–and it’s got deals with Big Pharma potentially worth over $4 billion

Read the full post on Forbes - Healthcare

This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make Billions

Alex Knapp, Forbes Staff

Most Recent